Edgar Filing: TITAN PHARMACEUTICALS INC - Form 3

TITAN PHARMACEUTICALS INC Form 3 January 06, 2017 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number: 3235-0104 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person <u>*</u> Smith Scott Andrew			2. Date of Event Requiring Statement (Month/Day/Year)	3. Issuer Name and Ticker or Trading Symbol TITAN PHARMACEUTICALS INC [TTNP]				
(Last)	(First)	(Middle)	01/02/2017		4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)	
5 ROUND TOP ROAD, 86 MORRIS AVENUE				(Check	all applicable)			
				X Directo Officer (give title belo			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 	
OLDWICK, NJ 08858								
(City)	(State)	(Zip)	Table I -	Non-Deriva	tive Securiti	es Be	neficially Owned	
1.Title of Securit (Instr. 4)	у		2. Amount Beneficiall (Instr. 4)	of Securities y Owned	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nat Owne (Instr.	*	
Reminder: Repor owned directly or	-	ate line for ea	ch class of securities benef	cially S	SEC 1473 (7-02)		
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Beneficially Owned (<i>e.g.</i> , puts, calls, warrants, options, convertible securities)								

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Security	Derivative Security: Direct (D) or Indirect (I)	

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 3

(Instr 5)

					(11su. 5)	
Stock Option (Right to Buy)	(1)	01/02/2027 Common Stock	ⁿ 5,000	\$4	D	Â

Reporting Owners

Reporting Owner Name / Add	lress	Relationships					
1 8 8 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		10% Owner	Officer	Other			
Smith Scott Andrew 5 ROUND TOP ROAD 86 MORRIS AVENUE OLDWICK, NJ 08858	ÂX	Â	Â	Â			
Signatures							
/s/ Scott Smith	01/04/2017						
<u>**</u> Signature of Reporting Person	Date						

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Vests in 12 equal monthly installments commencing on the date of grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.